Axion’s MEA systems can replicate a brainwave or a heartbeat in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives.
Axion’s MEA systems provide a label-free in vitro platform for direct measurement of electrical activity in neurons and cardiomyocytes, while the efficiency and convenience of Axion’s standard MEA plates facilitate use for screening-level applications. The large number of electrodes per well reveals detailed information about systems-level signal propogation.
Visit Us at the 2013 Society of Toxicology Meeting
Axion will be featured on two posters at this year’s annual meeting. Visit us at either one to learn more about our applications. Monday Morning, March 11 9:30 AM to 12:30 PM Exhibit Hall C–D Displayed: 9:30 AM–12:30 PM Author Attended: 9:30 AM–11:00 AM Abstract #89 Poster Board #123 Development of an In Vitro Multiwell [...]
Cyprotex Launches New Cardiotoxicity Service Using Axion’s Maestro System
Cyprotex PLC (AIM:CRX), the specialist preclinical contract research organization (CRO), today announces the launch of eCiphrCardio, an assay to assess potential cardiotoxicity of compounds in early drug development. This assay is based on microelectrode array (MEA) technology using Axion’s Maestro Multiwell MEA platform. Visit Source